Targeting T cells for asthma

IH Heijink; AJM Van Oosterhout

doi:10.1016/j.coph.2005.04.002

Targeting T cells for asthma

IH Heijink, AJM Van Oosterhout^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

22 Citations (Scopus)

Abstract

The type 2 T-helper (Th2) lymphocyte can be regarded as an important target cell for the treatment of allergic asthma as it plays a crucial role in the initiation, progression and persistence of disease. Several strategies to target Th2 cells can be envisioned. Drugs that prevent Th2-cells from migrating into the lung tissue, such as antibodies to the chemokine receptor CCR4 and inhibitors of the adhesion molecule VLA-4, are promising for the treatment of asthma. To inhibit Th2-cell activation, novel asthma drugs that act on Th2-selective transciption factors such as GATA3 are being developed. Although initial strategies aimed to block the action of Th2-derived cytokines, the generation of counter-regulatory Th1 lymphocytes and regulatory T cells is currently being explored.

Original language	English
Pages (from-to)	227-231
Number of pages	5
Journal	Current Opinion in Pharmacology
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/j.coph.2005.04.002
Publication status	Published - Jun-2005

Keywords

ALLERGIC AIRWAY INFLAMMATION
ACTIVATED-RECEPTOR-GAMMA
TRANSCRIPTION FACTOR
GENE-EXPRESSION
TH2 CELLS
ATOPIC ASTHMATICS
DENDRITIC CELLS
MOUSE MODEL
GATA-3
DISEASE

Access to Document

10.1016/j.coph.2005.04.002

Handle.net

Persistent link

Embargoed Document

Targeting T cells for asthma
Final publisher's version, 246 KB
Request copy

Cite this

@article{f606dbc66620498ab207a6d7a2466870,

title = "Targeting T cells for asthma",

abstract = "The type 2 T-helper (Th2) lymphocyte can be regarded as an important target cell for the treatment of allergic asthma as it plays a crucial role in the initiation, progression and persistence of disease. Several strategies to target Th2 cells can be envisioned. Drugs that prevent Th2-cells from migrating into the lung tissue, such as antibodies to the chemokine receptor CCR4 and inhibitors of the adhesion molecule VLA-4, are promising for the treatment of asthma. To inhibit Th2-cell activation, novel asthma drugs that act on Th2-selective transciption factors such as GATA3 are being developed. Although initial strategies aimed to block the action of Th2-derived cytokines, the generation of counter-regulatory Th1 lymphocytes and regulatory T cells is currently being explored.",

keywords = "ALLERGIC AIRWAY INFLAMMATION, ACTIVATED-RECEPTOR-GAMMA, TRANSCRIPTION FACTOR, GENE-EXPRESSION, TH2 CELLS, ATOPIC ASTHMATICS, DENDRITIC CELLS, MOUSE MODEL, GATA-3, DISEASE",

author = "IH Heijink and {Van Oosterhout}, AJM",

note = "J eview",

year = "2005",

month = jun,

doi = "10.1016/j.coph.2005.04.002",

language = "English",

volume = "5",

pages = "227--231",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "ELSEVIER SCI LTD",

number = "3",

}

TY - JOUR

T1 - Targeting T cells for asthma

AU - Heijink, IH

AU - Van Oosterhout, AJM

N1 - J eview

PY - 2005/6

Y1 - 2005/6

N2 - The type 2 T-helper (Th2) lymphocyte can be regarded as an important target cell for the treatment of allergic asthma as it plays a crucial role in the initiation, progression and persistence of disease. Several strategies to target Th2 cells can be envisioned. Drugs that prevent Th2-cells from migrating into the lung tissue, such as antibodies to the chemokine receptor CCR4 and inhibitors of the adhesion molecule VLA-4, are promising for the treatment of asthma. To inhibit Th2-cell activation, novel asthma drugs that act on Th2-selective transciption factors such as GATA3 are being developed. Although initial strategies aimed to block the action of Th2-derived cytokines, the generation of counter-regulatory Th1 lymphocytes and regulatory T cells is currently being explored.

AB - The type 2 T-helper (Th2) lymphocyte can be regarded as an important target cell for the treatment of allergic asthma as it plays a crucial role in the initiation, progression and persistence of disease. Several strategies to target Th2 cells can be envisioned. Drugs that prevent Th2-cells from migrating into the lung tissue, such as antibodies to the chemokine receptor CCR4 and inhibitors of the adhesion molecule VLA-4, are promising for the treatment of asthma. To inhibit Th2-cell activation, novel asthma drugs that act on Th2-selective transciption factors such as GATA3 are being developed. Although initial strategies aimed to block the action of Th2-derived cytokines, the generation of counter-regulatory Th1 lymphocytes and regulatory T cells is currently being explored.

KW - ALLERGIC AIRWAY INFLAMMATION

KW - ACTIVATED-RECEPTOR-GAMMA

KW - TRANSCRIPTION FACTOR

KW - GENE-EXPRESSION

KW - TH2 CELLS

KW - ATOPIC ASTHMATICS

KW - DENDRITIC CELLS

KW - MOUSE MODEL

KW - GATA-3

KW - DISEASE

U2 - 10.1016/j.coph.2005.04.002

DO - 10.1016/j.coph.2005.04.002

M3 - Review article

C2 - 15907907

SN - 1471-4892

VL - 5

SP - 227

EP - 231

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

IS - 3

ER -

Targeting T cells for asthma

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this